logo
logo

Organicell Regenerative Medicine, Inc. Closes $5.5 Million Funding Round

Aug 26, 2022•almost 3 years ago

Amount Raised

$5.5 Million

Miami

Description

MIAMI, FL / August 26, 2022 / Organicell Regenerative Medicine, Inc. (OTCQB:OCEL), a clinical-stage biopharmaceutical company principally focused on the development of innovative regenerative medicine and biological therapeutics, has closed its previously announced $4.0 million capital raise at $0.02 and corporate restructuring transaction. Organicell also closed on an additional $1.5 million of funding at $0.04 per share from two additional investors, totaling $5.5 million in funding.

Company Information

Company

Organicell Regenerative Medicines

Location

Miami, Florida, United States

About

Organicell Regenerative Medicine, Inc. (OTCQB:OCEL) is a clinical-stage biopharmaceutical company principally focusing on the development of innovative biological therapeutics for the treatment of degenerative diseases and the provision of other related services. The Company's proprietary products are derived from perinatal sources and manufactured to retain the naturally occurring exosomes, hyaluronic acid, and proteins without the addition or combination of any other substance or diluent. To learn more, please visit https://organicell.com/.

Related People